BIO logo

Bio-Rad Laboratories, Inc. Stock Price

NYSE:BIO Community·US$8.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 16 Fair Values set on narratives written by author

BIO Share Price Performance

US$0
-219.31 (-100.00%)
US$293.00
Fair Value
US$0
-219.31 (-100.00%)
Price US$0

BIO Community Narratives

·
Fair Value US$293 0.5% overvalued intrinsic discount

BIO: Expanded Diagnostics Partnership Will Drive Margin Improvements Amid Mixed Revenue Outlook

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
·
Fair Value US$325 9.4% undervalued intrinsic discount

Increasing Price Controls Will Limit Diagnostics Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$320 8.0% undervalued intrinsic discount

Global Healthcare Trends Will Fuel ddPCR Expansion Despite Risks

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$325
9.4% undervalued intrinsic discount
Profit Margin
9%
Future PE
40.76x
Price in 2029
US$409.31

Trending Discussion

Updated Narratives

BIO logo

BIO: Activist Pressure And Buybacks Will Shape Future Value Realization

Fair Value: US$320 8.0% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
BIO logo

BIO: Share Repurchases Will Support Future Upside Despite Lower Margin Outlook

Fair Value: US$293 0.5% overvalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
BIO logo

BIO: Fair Outlook Will Balance Richer Margins Against Higher Required Returns

Fair Value: US$325 9.4% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet and overvalued.

1 Risk
2 Rewards

Bio-Rad Laboratories, Inc. Key Details

US$2.6b

Revenue

US$1.2b

Cost of Revenue

US$1.3b

Gross Profit

US$1.2b

Other Expenses

US$168.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
6.31
52.01%
6.52%
17.4%
View Full Analysis

About BIO

Founded
1952
Employees
7450
CEO
Norman Schwartz
WebsiteView website
www.bio-rad.com

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Recent BIO News & Updates

Narrative Update Jun 04

BIO: Activist Pressure And Buybacks Will Shape Future Value Realization

Analysts have reaffirmed their $320.00 price target for Bio-Rad Laboratories, citing adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the main factors behind the updated view. What's in the News Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories after the stock declined more than 70% from its late 2021 peak, and is publicly pushing for improvements in the share price and company performance.

Recent updates

No updates